Nintedanib (BIBF 1120) for IPF: A tomorrow therapy?

16Citations
Citations of this article
40Readers
Mendeley users who have this article in their library.

Abstract

Idiopathic pulmonary fibrosis is a rare, life threatening disease characterized by an anarchic fibrogenesis, limited survival and few therapeutic options. Its pathogenesis is complex and involves the interaction among various pathways driven by proinflammatory/profibrogenetic mediators such as platelet -derived growth factor, vascular endothelial growth factor or basic fibroblast growth factor. Given their prominent pathogenic roles in this disease such growth factor might be suitable therapeutic targets.In fact, the existing preclinical and clinical data demonstrated that their therapeutic inhibition results in a delayed progression of the pulmonary fibrosis and in the improvement of the disease outcome. BIBF 1120 is a potent triple blocker of the receptors of these growth factors which is currently evaluated as a potential therapy in the idiopathic pulmonary fibrosis. This review discusses the existing data supporting its potential use in this disease. © 2012 Antoniu; licensee BioMed Central Ltd.

Cite

CITATION STYLE

APA

Antoniu, S. A. (2012). Nintedanib (BIBF 1120) for IPF: A tomorrow therapy? Multidisciplinary Respiratory Medicine. BioMed Central Ltd. https://doi.org/10.1186/2049-6958-7-41

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free